![Exatecan-amide-bicyclo[1.1.1]pentan-1-ol](https://file.medchemexpress.com/product_pic/hy-160597.gif "Click to View Exatecan-amide-bicyclo[1.1.1]pentan-1-ol Product Detail")
Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
24 Results for "
exatecan payload
" in MedChemExpress (MCE) Product Catalog:
Products (24)
24 Results for "exatecan payload" in MCE Product Catalog:
Cat. No.: HY-177434
CAS No.: 2873366-83-5
Synonyms: Precem-TcT; M 9140
Cat. No.: HY-164835
CAS No.: 2760408-75-9
Synonyms: VcMMAE-(PAB-GGFG-AMAA)exatecan; SMP-54418
Research Areas:
VcMMAE-Deruxtecan (VcMMAE-(PAB-GGFG-AMAA)Exatecan; SMP-54418) is a drug-linker conjugate for ADC, composed of linker-payload molecule conjugate VcMMAE (HY-15575) and linker-payload molecule conjugate Deruxtecan (PAB-GGFG-AMAA)Exatecan) (HY-13631E). VcMMAE-Deruxtecan can be used in the synthesis of ADCs.
Cat. No.: HY-79490
CAS No.: 2922852-48-8
Target:
Research Areas:
Ac-Exatecan is acetylation-modified Exatecan (HY-13631). Exatecan is a common toxin component in ADC preparation (ADC cytotoxin) and an inhibitor of DNA topoisomerase I (IC50 = 2.2 μM). Exatecan has antitumor activity. Exatecan can be used as a payload for ADC. Exatecan is effective against P-glycoprotein mediated multi-drug resistant cells .
Cat. No.: HY-176415
CAS No.: 3025787-83-8
Target:
Research Areas:
Cys-MC-GGFG-Dxd is a cysteine-modified, cleavable ADC drug-linker conjugate. Cys-MC-GGFG-Dxd consists of a maleimidocaproyl-glycine-glycine-L-phenylalanine-glycine (MC-GGFG) linker and an Exatecan (HY-13631) derivative (DXd) (HY-13631D) payload. Cys-MC-GGFG-Dxd can be further conjugated to anti-HER2 IgG1κ antibody for the synthesis of antibody-drug conjugates (ADC), such as the breast cancer-targeting ADC compound Fam-trastuzumab deruxtecan-nxki (Enhertu) .
Cat. No.: HY-163099
CAS No.: 2928571-43-9
Research Areas:
P5 (PEG24)-VC-PAB-Exatecan is a TOP1 inhibitor payload with antibody-conjugation-dependent activity. Conjugation of P5 (PEG24)-VC-PAB-Exatecan with Trastuzumab (HY-P9907) generates a DAR8 antibody-drug conjugate (ADCs) with antibody-like pharmacokinetic properties. P5 (PEG24)-VC-PAB-Exatecan induces S-phase and G2-M-phase cell cycle arrest, DNA damage and apoptosis in target-positive tumor cells, and releases damage-associated molecular patterns (DAMP) related to immunogenic cell death (ICD). The ADCs prepared from it exert bystander killing effects on non-target tumor cells. ADCs based on P5 (PEG24)-VC-PAB-Exatecan exhibit linker stability in vitro and in vivo, show in vivo efficacy, and can be used in research related to HER2-positive cancers .
Cat. No.: HY-160885A
Research Areas:
NH2-Gly-PAB-Exatecan-D-glucuronic acid formic (Compound 8) is an intermediate that reacts with NHS-group-containing molecules to generate the ADC drug-linker conjugate Mal-Gly-PAB-Exatecan-D-glucuronic acid (HY-153179) .
Cat. No.: HY-176976
CAS No.: 3076725-05-5
Target:
Research Areas:
Exatecan-mpGNNG (Compound 10a) is the linker-payload component of an antibody-drug conjugate (ADC). Exatecan-mpGNNG is composed of Exatecan (HY-13631), a potent topoisomerase I inhibitor, and the linker .
Cat. No.: HY-160806
CAS No.: 2813268-66-3
Target:
Research Areas:
(5-Cl)-Exatecan is a derivative of Exatecan (HY-13631) and a DNA topoisomerase inhibitor. (5-Cl)-Exatecan serves as the cytotoxic payload component in antibody-drug conjugates (ADC) targeting ROR1-positive cancers. (5-Cl)-Exatecan is applicable for the research of ROR1-positive cancers .
Cat. No.: HY-173703
CAS No.: 3025108-11-3
Research Areas:
β-Glu-PAB (CH2NH2)-Exatecan is a linker-payload conjugate composed of Exatecan (HY-13631) and β-Glu-PAB (CH2NH2). β-Glu-PAB (CH2NH2)-Exatecan also serves as an intermediate of Mal ((3S,3aR,6S,6aR)-Hexahydrofuro[3,2-b]furan-3,6-diamine-PEG12)-β-Glu-PAB-Exatecan (HY-173634). β-Glu-PAB (CH2NH2)-Exatecan is specifically cleaved by β-glucuronidase, which is highly expressed in the tumor microenvironment, to release Exatecan that exerts cytotoxic effects. β-Glu-PAB (CH2NH2)-Exatecan can be used in cancer research .
Cat. No.: HY-160597
CAS No.: 2866299-06-9
Target:
Research Areas:
Exatecan-amide-bicyclo[1.1.1]pentan-1-ol (Compound 79) is an exatecan (HY-13631) derivative that can be used as a payload in drug conjugates. Exatecan-amide-bicyclo[1.1.1]pentan-1-ol has significant inhibitory activity against a variety of tumor cell lines .
Cat. No.: HY-169324
CAS No.: 2921735-91-1
Synonyms: Mal-Exo-EEVC-exatecan
Target:
Research Areas:
APL-1092 is an EEVC linker-payload conjugate composed of exatecan, a stabilizer that prevents premature payload release, and a cleavage substrate for cathepsin B . APL-1092 resists premature payload release mediated by human neutrophil elastase and carboxylesterase, maintains payload stability in mouse plasma, and retains cathepsin B-mediated cleavage activity in target cells . APL-1092 exhibits dose-dependent tumor growth inhibition in xenograft mice . APL-1092 can be used in gastric cancer-related research .
Cat. No.: HY-160806A
Target:
Research Areas:
(5-Cl)-Exatecan TFA is a derivative of Exatecan (HY-13631) and a DNA topoisomerase inhibitor. (5-Cl)-Exatecan TFA serves as the cytotoxic payload component in antibody-drug conjugates (ADC) targeting ROR1-positive cancers. (5-Cl)-Exatecan TFA is applicable for the research of ROR1-positive cancers .
Cat. No.: HY-160756
CAS No.: 2952679-21-7
Research Areas:
Val-Cit-Exatecan is a peptide-linked anti-tumor payload that can be used for the synthesis of antibody-drug conjugates (ADC). Val-Cit-Exatecan consists of DNA TopI inhibitor Exatecan (HY-13631) and a cathepsin-cleavable ADC linker (valine-citrulline). Val-Cit-Exatecan can be used in the research of colorectal cancer, gastric cancer, breast cancer, non-small cell lung cancer, ovarian cancer, head and neck cancer, pancreatic cancer, cervical cancer, and melanoma .
Cat. No.: HY-183523
CAS No.: 2925458-10-0
Synonyms: CPT-113
Target:
Research Areas:
Bis-Mal-Suc-PEG10-bis(triAla)-Exatecan (CPT-113) is a cytotoxic payload/linker conjugate that forms antibody-drug conjugates (ADCs) with bispecific EGFR/Muc1 antibodies. Bis-Mal-Suc-PEG10-bis(triAla)-Exatecan is applicable for ADC synthesis .
Cat. No.: HY-186185
CAS No.: 3091519-75-1
Research Areas:
OSu-Val-Cit-PAB-Exa (compound D) is a cleavable linker-payload conjugate (usable for ADC synthesis). OSu-Val-Cit-PAB-Exa bears an N-terminal N-hydroxysuccinimide (OSu) ester group, and comprises Val-Cit, p-aminobenzyl alcohol (PAB) and Exatecan (HY-13631). OSu-Val-Cit-PAB-Exa serves as a payload-linker intermediate for polypeptide conjugation .
Cat. No.: HY-185101
Target:
Research Areas:
MC-AcLys-GDEVD-PABC-Exatecan (MC-AcLys-GDEVD-PABC-DX8951) is a agent-linker conjugate for ADC. MC-AcLys-GDEVD-PABC-Exatecan is a DX8951 (a DNA topoisomerase I inhibitor) derivative with a novel caspase-3 cleavable peptide linker MC-AcLys-GDEVD-PABC linker. MC-AcLys-GDEVD-PABC-Exatecan can be used to prepare DX8951 antibody conjugate (ADC), and it exhibites significant bystander effect mediated by the caspase-3-triggered extracellular cleavage of the linker, enhancing payload release into the tumor microenvironment.
Cat. No.: HY-183594
CAS No.: 3037373-65-9
Target:
Research Areas:
Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal is a linker-payload conjugate. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal contains the linker D-2,4-DHB-NH2-AA(bPEG8)-Mal (HY-183595) and the cytotoxic agent Exatecan (HY-13631), a potent DNA topoisomerase I inhibitor. Exatecan-(D-2,4-DHB)-NH2-AA (bPEG8)-Mal can be utilized for the development of antibody-drug conjugates (ADCs) .
Cat. No.: HY-181679
Target:
Research Areas:
TML-2Cl is a dichloro-modified trimethyl lock adapter for antibody-drug conjugates and payload releaser.TML-2Cl undergoes 1,6-elimination followed by rapid self-cyclization to facilitate release of the payload Exatecan after cathepsin B cleavage of the associated linker.TML-2Cl exhibits high stability when conjugated to a drug and high intrinsic hydrophobicity.TML-2Cl can be used for the research of gastric carcinoma .
Cat. No.: HY-184905
Target:
Research Areas:
W1507 is an NH2-TML-based linker-payload conjugate, in which the payload is Exatecan (HY-13631) and the linker is Mal-PEG4-Val-Ala-Ph-2,2-dimethylpropanoic acid (HY-184906). W1507 can be conjugated with Trastuzumab (HY-P9907) to synthesize the ADC Her2-W1507. Her2-W1507 exhibits in vivo anti-tumor activity. W1507 can be used for the research of gastric cancer, ovarian adenocarcinoma and Her2-amplified breast cancer .
Cat. No.: HY-188015
CAS No.: 3086791-85-4
Target:
Research Areas:
DBCO-PEG4-GGFG-Triptolide is a triptolide-based antibody-drug conjugate (ADC) payload, consisting of a DBCO click chemistry reactive group, a PEG4 linker, a cathepsin-cleavable GGFG peptide segment, and triptolide. DBCO-PEG4-GGFG-Triptolide binds to antibodies via glycosylation conjugation, releases active triptolide intracellularly to exert cytotoxic effects, and is commonly used in combination with camptothecin-class toxins (Exatecan (HY-13631) / DXd (HY-13631D)) for the preparation of dual-toxin ADCs .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
